gymnema sylvestre glp-1 study Supplementation Restores Normoglycemia, Corrects Dyslipidemia, and Transcriptionally Modulates Pancreatic and Hepatic Gene Expression in Alloxan-Induced Hyperglycemic Rats Exploring the anti-diabetic mechanism of

5-7% Study after study has shown that patients with prediabetes who lost even 5-7% of their weight prevented progression to type 2 diabetes

"By shifting GLP-1 exposure toward the brain and away from the periphery, our technology directly addresses key limitations of current injectable and oral GLP-1 therapies." A next-generation GLP-1 strategy Current subcutaneous and oral GLP-1 receptor agonists generate high plasma levels but achieve only limited direct brain exposure, contributing to dose-limiting gastrointestinal side effects and restricting their broader use in CNS-driven indications

Though several molecules, such as mazdutide, a GLP/glucagon dual agonist, are being studied in various phases, the first agent targeting incretins other than just GLP-1 was approved in 2022 tirzepatide [41]

Gerti Tashko, MD, is a board-certified endocrinologist based in Montgomery County, Maryland

doi: 10.1523/jneurosci.23-14-05998.2003

(In: Lefbvre PJ, ed